Terms: = Skin cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S
99 results:
1. Exposure to benzene and other hydrocarbons and risk of bladder cancer among male offshore petroleum workers.
Shala NK; Stenehjem JS; Babigumira R; Liu FC; Berge LAM; Silverman DT; Friesen MC; Rothman N; Lan Q; Hosgood HD; Samuelsen SO; Bråtveit M; Kirkeleit J; Andreassen BK; Veierød MB; Grimsrud TK
Br J Cancer; 2023 Sep; 129(5):838-851. PubMed ID: 37464024
[TBL] [Abstract] [Full Text] [Related]
2. Molecular and clinical correlates of her3 expression highlights its potential role as a therapeutic target in melanoma.
Shteinman ER; Vergara IA; Rawson RV; Lo SN; Maeda N; Koyama K; da Silva IP; Long GV; Scolyer RA; Wilmott JS; Menzies AM
Pathology; 2023 Aug; 55(5):629-636. PubMed ID: 37286471
[TBL] [Abstract] [Full Text] [Related]
3. Functional genomics of human clear cell sarcoma: genomic, transcriptomic and chemical biology landscape for clear cell sarcoma.
Rasmussen SV; Wozniak A; Lathara M; Goldenberg JM; Samudio BM; Bickford LR; Nagamori K; Wright H; Woods AD; Chauhan S; Lee CJ; Rudzinski ER; Swift MK; Kondo T; Fisher DE; Imyanitov E; Machado I; Llombart-Bosch A; Andrulis IL; Gokgoz N; Wunder J; Mirotaki H; Nakamura T; Srinivasa G; Thway K; Jones RL; Huang PH; Berlow NE; Schöffski P; Keller C
Br J Cancer; 2023 May; 128(10):1941-1954. PubMed ID: 36959380
[TBL] [Abstract] [Full Text] [Related]
4. Collectin-11 promotes cancer cell proliferation and tumor growth.
Wang JX; Cao B; Ma N; Wu KY; Chen WB; Wu W; Dong X; Liu CF; Gao YF; Diao TY; Min XY; Yong Q; Li ZF; Zhou W; Li K
JCI Insight; 2023 Mar; 8(5):. PubMed ID: 36883567
[TBL] [Abstract] [Full Text] [Related]
5. Cooperative induction of receptor tyrosine kinases contributes to adaptive MAPK drug resistance in melanoma through the PI3K pathway.
Alver TN; Heintz KM; Hovig E; Bøe SL
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1736. PubMed ID: 36251678
[TBL] [Abstract] [Full Text] [Related]
6. Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome.
Viktorsson K; Hååg P; Shah CH; Franzén B; Arapi V; Holmsten K; Sandström P; Lewensohn R; Ullén A
Mol Oncol; 2022 Oct; 16(20):3620-3641. PubMed ID: 35838333
[TBL] [Abstract] [Full Text] [Related]
7. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
DiNardo CD; Lachowiez CA; Takahashi K; Loghavi S; Kadia T; Daver N; Xiao L; Adeoti M; Short NJ; Sasaki K; Wang SA; Borthakur G; Issa G; Maiti A; Alvarado Y; Pemmaraju N; Bravo GM; Masarova L; Yilmaz M; Jain N; Andreeff M; Garcia-Manero G; Kornblau S; Ravandi F; Jabbour E; Konopleva MY; Kantarjian HM
Am J Hematol; 2022 Aug; 97(8):1035-1043. PubMed ID: 35583199
[TBL] [Abstract] [Full Text] [Related]
8. Targeting erbb3 and Cellular NADPH/NADP
Leu JI; Murphy ME; George DL
ACS Chem Biol; 2022 May; 17(5):1038-1044. PubMed ID: 35420772
[TBL] [Abstract] [Full Text] [Related]
9. Loss of Tpl2 activates compensatory signaling and resistance to EGFR/MET dual inhibition in v-RAS transduced keratinocytes.
Kelley MB; Geddes TJ; Ochiai M; Lampl NM; Kothmann WW; Fierstein SR; Kent V; DeCicco-Skinner K
PLoS One; 2022; 17(3):e0266017. PubMed ID: 35325006
[TBL] [Abstract] [Full Text] [Related]
10. First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
Berlin J; Tolcher AW; Ding C; Whisenant JG; Horak ID; Wood DL; Nadler PI; Hansen UH; Lantto J; Skartved NJØ; Pedersen MW; Patnaik A
Invest New Drugs; 2022 Jun; 40(3):586-595. PubMed ID: 35113285
[TBL] [Abstract] [Full Text] [Related]
11. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
12. The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.
Hoesl C; Fröhlich T; Posch C; Kneitz H; Goebeler M; Schneider MR; Dahlhoff M
Mol Oncol; 2021 Aug; 15(8):2140-2155. PubMed ID: 33786987
[TBL] [Abstract] [Full Text] [Related]
13. Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.
Estrada-Bernal A; Le AT; Doak AE; Tirunagaru VG; Silva S; Bull MR; Smaill JB; Patterson AV; Kim C; Liu SV; Doebele RC
Clin Cancer Res; 2021 Mar; 27(5):1463-1475. PubMed ID: 33355298
[TBL] [Abstract] [Full Text] [Related]
14. Unbiased Detection of Driver Mutations in Extramammary Paget Disease.
Ishida Y; Kakiuchi N; Yoshida K; Inoue Y; Irie H; Kataoka TR; Hirata M; Funakoshi T; Matsushita S; Hata H; Uchi H; Yamamoto Y; Fujisawa Y; Fujimura T; Saiki R; Takeuchi K; Shiraishi Y; Chiba K; Tanaka H; Otsuka A; Miyano S; Kabashima K; Ogawa S
Clin Cancer Res; 2021 Mar; 27(6):1756-1765. PubMed ID: 33323405
[TBL] [Abstract] [Full Text] [Related]
15. Novel ex vivo disease model for extramammary Paget's disease using the cancer tissue-originated spheroid method.
Arita T; Kondo J; Kaneko Y; Tsutsumi M; Kanemaru M; Matsui M; Arakawa Y; Katoh N; Inoue M; Asai J
J Dermatol Sci; 2020 Sep; 99(3):185-192. PubMed ID: 32800410
[TBL] [Abstract] [Full Text] [Related]
16. Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma.
Tiago M; Capparelli C; Erkes DA; Purwin TJ; Heilman SA; Berger AC; Davies MA; Aplin AE
Br J Cancer; 2020 Mar; 122(6):789-800. PubMed ID: 31932756
[TBL] [Abstract] [Full Text] [Related]
17. Dual Erb B Inhibition in Oesophago-gastric cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma.
Thomas A; Virdee PS; Eatock M; Lord SR; Falk S; Anthoney DA; Turkington RC; Goff M; Elhussein L; Collins L; Love S; Moschandreas J; Middleton MR
Eur J Cancer; 2020 Jan; 124():131-141. PubMed ID: 31765988
[TBL] [Abstract] [Full Text] [Related]
18. Distant metastasis due to heavily pigmented epithelioid melanoma with underlying BRAF V600E, NOTCH1, erbb3, and PTEN mutations.
Motaparthi K; George EV; Guo R
J Cutan Pathol; 2019 Aug; 46(8):613-618. PubMed ID: 31025390
[TBL] [Abstract] [Full Text] [Related]
19. Cross-Talk between Receptor Tyrosine Kinases AXL and erbb3 Regulates Invadopodia Formation in Melanoma Cells.
Revach OY; Sandler O; Samuels Y; Geiger B
Cancer Res; 2019 May; 79(10):2634-2648. PubMed ID: 30914429
[TBL] [Abstract] [Full Text] [Related]
20. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract] [Full Text] [Related]
[Next]
